Detalles de la búsqueda
1.
Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study.
Genet Med
; 24(12): 2444-2452, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36107167
2.
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Lancet
; 396(10252): 684-692, 2020 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32891212
3.
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Genet Med
; 23(12): 2443-2447, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34341520
4.
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
Clin Pharmacokinet
; 63(5): 707-719, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649657
5.
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Child Adolesc Health
; 8(1): 40-50, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37984383
6.
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Clin Pharmacokinet
; 61(2): 263-280, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431071
7.
Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
Sci Prog
; 104(1): 368504211003782, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761804
8.
Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia.
Sci Rep
; 11(1): 24278, 2021 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34930956
9.
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Lancet Rheumatol
; 2(11): e666-e676, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279363
10.
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study.
Lancet Rheumatol
; 2(11): e677-e688, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279364
11.
Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.
PLoS One
; 9(2): e87379, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24498318
12.
Design of the tocilizumab in giant cell arteritis trial.
Int J Rheumatol
; 2013: 912562, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23653652
Resultados
1 -
12
de 12
1
Próxima >
>>